Evidence map›Paper›PMID 31382955›Full record

ArticleRespiratory research2019

Mass spectrometry imaging as a tool for evaluating the pulmonary distribution of exogenous surfactant in premature lambs.

Riccardo Zecchi, Pietro Franceschi, Laura Tigli, Francesca Ricci, Francesca Boscaro, Barbara Pioselli, Valentina Mileo, Xabier Murgia, Federico Bianco, Fabrizio Salomone and 4 more

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Riccardo ZecchiMass Spectrometry Service Center (CISM), University of Florence, Florence, Italy.
Pietro FranceschiComputational Biology, Research and Innovation Centre, Fondazione Edmund Mach, S. Michele all'Adige, TN, Italy.
Laura TigliPreclinical R&D, Chiesi Farmaceutici, Largo Francesco Belloli, 11/A, 43122, Parma, Italy.
Francesca RicciPreclinical R&D, Chiesi Farmaceutici, Largo Francesco Belloli, 11/A, 43122, Parma, Italy.
Francesca BoscaroMass Spectrometry Service Center (CISM), University of Florence, Florence, Italy.
Barbara PioselliPreclinical R&D, Chiesi Farmaceutici, Largo Francesco Belloli, 11/A, 43122, Parma, Italy.
Valentina MileoPreclinical R&D, Chiesi Farmaceutici, Largo Francesco Belloli, 11/A, 43122, Parma, Italy.
Xabier MurgiaScientific Consultancy, Saarbrücken, Germany.
Federico BiancoPreclinical R&D, Chiesi Farmaceutici, Largo Francesco Belloli, 11/A, 43122, Parma, Italy.
Fabrizio SalomonePreclinical R&D, Chiesi Farmaceutici, Largo Francesco Belloli, 11/A, 43122, Parma, Italy. f.salomone@chiesi.com.
Augusto F SchmidtDivision of Neonatology and Pulmonary Biology, Cincinnati Children's Hospital, Cincinnati, USA.
Noah H HillmanDivision of Neonatology, Cardinal Glennon Children's Hospital, Saint Louis University, Saint Louis, USA.
Matthew W KempDivision of Obstetrics and Gynecology, University of Western Australia, Perth, WA, Australia.
Alan H JobeDivision of Neonatology, Cardinal Glennon Children's Hospital, Saint Louis University, Saint Louis, USA.
Chiesi Foundation · ITUniversity of Florence · ITUniversity of Western Australia · AUCardinal Glennon Children’s Medical Center · USCincinnati Children's Hospital Medical Center · USFondazione Edmund Mach · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe amount of surfactant deposited in the lungs and its overall pulmonary distribution determine the therapeutic outcome of surfactant replacement therapy. Most of the currently available methods to determine the intrapulmonary distribution of surfactant are time-consuming and require surfactant labelling. Our aim was to assess the potential of Mass Spectrometry Imaging (MSI) as a label-free technique to qualitatively and quantitatively evaluate the distribution of surfactant to the premature lamb.

methodsTwelve preterm lambs (gestational age 126-127d, term ~150d) were allocated in two experimental groups. Seven lambs were treated with an intratracheal bolus of the synthetic surfactant CHF5633 (200 mg/kg) and 5 lambs were managed with mechanical ventilation for 120 min, as controls. The right lung lobes of all lambs were gradually frozen while inflated to 20 cmH

resultsSurfactant treatment was associated with a significant improvement of the mean arterial oxygenation and lung compliance (p < 0.05). Nevertheless, the physiological response to surfactant treatment was not uniform across all animals. SP-C analog and SP-B analog were successfully imaged and quantified by means of MSI in the peripheral lungs of all surfactant-treated animals. The intensity of the signal was remarkably low in untreated lambs, corresponding to background noise. The signal intensity of SP-B analog in each surfactant-treated animal, which represents the surfactant distributed to the peripheral right lung, correlated well with the physiologic response as assessed by the area under the curves of the individual arterial partial oxygen pressure and dynamic lung compliance curves of the lambs.

conclusionsApplying MSI, we were able to detect, locate and quantify the amount of exogenous surfactant distributed to the lower right lung of surfactant-treated lambs. The distribution pattern of SP-B analog correlated well with the pulmonary physiological outcomes of the animals. MSI is a valuable label-free technique which is able to simultaneously evaluate qualitative and quantitative drug distribution in the lung.

Indexed as

AnimalsAnimals, NewbornLungMass SpectrometryPeptide FragmentsPhosphatidylcholinesPulmonary Surfactant-Associated Protein BPulmonary Surfactant-Associated Protein CPulmonary SurfactantsSheepTissue DistributionCHF5633Peptide FragmentsPhosphatidylcholinesPulmonary Surfactant-Associated Protein BPulmonary Surfactant-Associated Protein CPulmonary SurfactantsCHF5633Mass spectrometry imagingPremature lambsRespiratory distress syndromeSurfactant

Identifiers

PMID31382955
PMCPMC6683365
OpenAlexW2966372052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.